Current Report · Items 5.07 · 8-K
Aptevo Therapeutics Inc.
APVONASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On September 22, 2026, Aptevo Therapeutics Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”), at which a quorum was present.…
Filed Sep 23, 2026Accepted Sep 23, 2026, 4:43 PM EDTCIK 1671584Accession 0001193125-26-399545
Company context
We are a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. We have developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs and have two clinical candidates and six preclinical candidates currently in development. Clinical candidate mipletamig is a CD123xCD3 T cell engager currently being clinically evaluated in the RAINIER trial, part one of a Phase 1b/2 program initiated in August 2024 for the treatment of frontline acute myelogenous leukemia (AML) in combination with standard of care venetoclax + azacitidine. Clinical candidate ALG.APV-527 targets 4-1BB (co-stimulatory receptor) and 5T4 (tumor antigen). The compound is designed to reactivate antigen-primed T cells to specifically kill tumor cells and is currently being evaluated for the treatment of multiple solid tumor types.
Current securities
Historical securities (1)
Disclosure sections
Items 5.07Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders.
On September 22, 2026, Aptevo Therapeutics Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”), at which a quorum was present. Stockholders considered four proposals outlined below, each of which is described in more detail in the Company’s definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission on August 31, 2026 (the “Proxy Statement”). The final voting results with respect to each of the proposals acted upon at the 2026 Special Meeting are set forth below.
Proposal 1: Approval of the Company's Amended and Restated Certificate of Incorporation
An amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to make certain technical and administrative changes was not approved based on the following:
FOR AGAINST ABSTAIN BROKER NON-VOTES
───────────────────────────────────────────────────────────
654,005 93,851 4,759 0
Proposal 2: Approval of the issuance of common stock
The issuance of more than 20% of the Company's issued and outstanding common stock as of August 12, 2026 pursuant to the warrant reload and private placement transactions with certain holders, pursuant to Nasdaq Listing Rules 5635(d) was approved based on the following:
FOR AGAINST ABSTAIN BROKER NON-VOTES
───────────────────────────────────────────────────────────
319,306 100,098 4,225 328,986
Proposal 3: Approval of the Company's Fifth Amended and Restated 2018 Stock Incentive Plan
The Aptevo Therapeutics Inc. Fifth Amended and Restated 2018 Stock Incentive Plan was approved based on the following votes:
FOR AGAINST ABSTAIN BROKER NON-VOTES
───────────────────────────────────────────────────────────
331,590 82,399 9,640 328,986
Proposal 4: Authorization to adjourn the Special Meeting
The authorization to adjourn the Special Meeting to a later date, if necessary or appropriate, was approved based on the following votes:
FOR AGAINST ABSTAIN BROKER NON-VOTES
───────────────────────────────────────────────────────────
639,823 92,829 19,963 0